
Armour Thyroid is owned by AbbVie Inc. (NYSE: ABBV), which acquired the brand through its $63 billion purchase of Allergan in 2020; Allergan had inherited it via Actavis's 2014 acquisition of Forest Laboratories. Armour Thyroid is a natural desiccated thyroid product made from porcine thyroid glands that has been used to treat hypothyroidism since the early 1900s.
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Armour Thyroid | AbbVie Inc. | Product line |
Armour Thyroid predates the modern pharmaceutical industry. Hypothyroidism treatment began in 1891 when British physician George Redmayne Murray reported successfully treating myxedema with sheep thyroid extract, and thyroid feeding spread through Europe and the United States in the following decades.
Armour and Company, the dominant American meatpacker, entered the business in the early 1900s. It was a natural fit: the company processed millions of hogs, and the thyroid glands were previously discarded offal. Armour dried, powdered, and standardized the glands and sold desiccated thyroid to apothecaries as an ingredient and, eventually, as a finished product. The Armour name became synonymous with thyroid extract, and porcine glands replaced bovine as the standard source.
For the first half of the twentieth century, desiccated thyroid was the only treatment for hypothyroidism, and at its 1960s peak natural thyroid accounted for roughly 80 percent of US thyroid prescriptions. Then came the shift to synthetic levothyroxine, which offered consistent hormone content that animal-derived product could not guarantee. Through the 1970s and 1980s, synthetic T4 replaced desiccated thyroid as the standard of care.
Armour survived the transition as the leading natural option. The brand's regulatory status is unusual: it predates the 1938 Food, Drug and Cosmetic Act and was grandfathered, meaning it has been legally marketed for more than a century without ever holding a modern New Drug Application.
Forest Laboratories owned the brand for much of the modern era. In 2009, Forest reformulated Armour Thyroid, increasing cellulose and reducing sucrose, a change that frustrated patients who had dissolved the tablet under the tongue and produced widespread complaints of returned hypothyroid symptoms. The episode illustrated how sensitive a committed patient base can be to even minor formulation changes.
Actavis's 2014 acquisition of Forest moved the brand again, and the combined company adopted the Allergan name in 2015. During this period the brand drew attention for price increases: Allergan raised the price roughly 50 percent in July 2015, citing manufacturing investment needs. AbbVie completed the latest transfer when it bought Allergan in May 2020.
Through the 1990s and 2000s, interest in natural medicine revived demand for desiccated thyroid among patients who felt poorly served by T4-only therapy. Armour Thyroid remains the best-known product in that niche, valued by its users for containing both T4 and T3 hormones naturally present in the gland.
What does AbbVie own?
AbbVie owns a portfolio of prescription drug brands including Skyrizi, Rinvoq, Humira, Imbruvica, Venclexta, Vraylar, Ubrelvy, Qulipta, and Elahere, plus the aesthetics products Botox Cosmetic and Juvederm acquired through the 2020 Allergan deal. All are internally held product brands rather than separate subsidiaries.
Is AbbVie publicly traded?
Yes. AbbVie trades on the New York Stock Exchange under ticker ABBV and is a component of the S&P 500. It has traded publicly since its January 2013 spin-off from Abbott Laboratories, and Abbott retains no ownership stake.
Who founded AbbVie?
AbbVie was not founded by individuals but created as a corporate spin-off from Abbott Laboratories in 2013, led at launch by CEO Richard A. Gonzalez. Its operating heritage traces to Dr. Wallace C. Abbott, who founded Abbott's predecessor drug company in Chicago in 1888.
Where is AbbVie headquartered?
AbbVie is headquartered in North Chicago, Illinois, in the same suburban Chicago corridor where Abbott has long been based. Its principal offices sit at 1 North Waukegan Road.
How many brands does AbbVie own?
AbbVie markets roughly a dozen major product brands, led by Skyrizi, Rinvoq, Humira, Botox, Juvederm, Imbruvica, and Venclexta, plus smaller products across eye care and neuroscience. Unlike consumer conglomerates, its brands are individual prescription medicines rather than retail labels.
Who owns AbbVie?
AbbVie is owned by public shareholders, with Vanguard, BlackRock, and State Street as the largest institutional holders. Robert A. Michael serves as chairman and chief executive officer. No founding family or single shareholder controls the company.
What happened to Humira?
U.S. biosimilar competitors launched in January 2023 after AbbVie's patent settlements allowed entry. Humira worldwide revenue fell from a $21.2 billion peak in 2022 to $4.54 billion in 2025, while Skyrizi and Rinvoq grew to replace it, pushing total company revenue to a record $61.16 billion.
The 2009 Forest Laboratories reformulation is the brand's most remembered controversy. The change in binders made the tablets unsuitable for the sublingual use some patients preferred, and many reported renewed hypothyroid symptoms. Patient communities document the episode extensively, and it drove some users to competing natural products.
Pricing is the second recurring issue. Allergan's roughly 50 percent price increase in July 2015 drew public attention, with the company justifying it on manufacturing investment. Desiccated thyroid products have generally seen price escalation over the past two decades as the category consolidated.
The structural controversy is regulatory status. Because the product predates the FDA's modern approval system and was grandfathered, critics periodically question whether grandfathered drugs should face modern efficacy requirements. The FDA has allowed continued marketing, but the product technically remains unapproved by contemporary standards, a status shared by other pre-1938 drugs.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Abbvie | USA | 1955 | Mass market | United states | All Genders | |
| Pfizer | USA | 2001 | Mass market | United states | All Genders | |
| Amneal Pharmaceuticals | USA | 2000 | Mass market | United states | All Genders | |
| Ibsa | Switzerland | 2006 | Premium | United states | All Genders | |
| Ibsa | Switzerland | 2016 | Mass market | United states | All Genders |
Healthcare PharmaceuticalsOwned by AbbVie Inc.
AbbVie's levothyroxine brand for hypothyroidism, first marketed in 1955 and long among the most prescribed medications in the United States.
Healthcare PharmaceuticalsOwned by Pfizer Inc.
Pfizer's levothyroxine brand for hypothyroidism, FDA approved in 2001 and inherited through the 2011 King Pharmaceuticals acquisition.
Healthcare PharmaceuticalsOwned by Amneal Pharmaceuticals, Inc.
Levothyroxine tablet for hypothyroidism, the first FDA-approved levothyroxine product, manufactured by Jerome Stevens Pharmaceuticals and distributed by Amneal.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Pharma's liquid levothyroxine oral solution, the first and only FDA-approved liquid levothyroxine, marketed in monodose ampules for hypothyroidism since 2019 in the US.
Market Positioning: Armour Thyroid competes with 5 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by AbbVie Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Tirosint is privately owned, unlike Armour Thyroid which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Pharma's liquid levothyroxine oral solution, the first and only FDA-approved liquid levothyroxine, marketed in monodose ampules for hypothyroidism since 2019 in the US.
Tirosint-SOL is privately owned, unlike Armour Thyroid which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by TTAM Research Institute
Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.
23andMe is privately owned, unlike Armour Thyroid which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Adcock Ingram Holdings Limited
South African pharmaceutical brand behind Panado and Myprodol, now privately held by Bidvest and NATCO Pharma.
Adcock Ingram is privately owned, unlike Armour Thyroid which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Global Medical Response
America's largest air ambulance membership network, covering more than 3 million members across 38 states, operated by Global Medical Response.
AirMedCare Network is privately owned, unlike Armour Thyroid which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Alfa-Pharm CJSC
Armenia's largest pharmaceutical distributor and pharmacy chain, importing medicines from more than 70 global manufacturers since 1996.
Alfa-Pharm is privately owned, unlike Armour Thyroid which is under a publicly traded parent company.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.